New User Account Set Up

If you do not have an account with the Digest, please click on "Submit to the Digest." By logging in with your UCLA Login ID (formerly known as BOL Login), a new account will automatically be generated. If you experience any difficulties, please send an email to our help desk:


If you have any questions or concerns, please email our help desk/support team: We are more than happy to address any questions or concerns regarding the Weekly Message Digest system you may have.

How do I subscribe?

If you have a mednet email account (, you should already be subscribed.

If you do not have a mednet email account or you are not receiving the Digest, please send an email to and we will add you to our list.

New Phase I Clinical Trial for HIV+ Individuals Who Are Undetectable

We are looking for HIV+ people who are taking antiretroviral treatment (ART) and whose viral load is undetectable. The goal is to find out if IL-15 is safe alone, or when used in combination with another treatment called broadly neutralizing antibodies (bNAbs). Participants will receive 8 doses of IL-15 given every 3 weeks. Half of the IL-15 participants will be randomly assigned to also receive the bNAbs with it. After completing these treatments, participants will temporarily stop taking their HIV medicine (ART) and will be evaluated to see how well this treatment controls their viral load.


Basic eligibility criteria:

  • Age 18 to 65 years old
  • HIV positive
  • On continuous HIV treatment (antiretroviral therapy) for at least 52 weeks
  • Undetectable HIV viral load for at least 52 weeks
  • CD4 cell count more than 450
  • No active Hepatitis B or C infection
  • Not pregnant or breastfeeding


Principal Investigator: Kara Chew, MD, MSc


For more information contact the UCLA study team at (310) 843-2015 or

Posting Information
This posting expired on February 24, 2022.
Posting Attachment: Download Attachment

Share this posting on social media!